Your browser doesn't support javascript.
loading
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
Gelfand, Joel M; Armstrong, April W; Bell, Stacie; Anesi, George L; Blauvelt, Andrew; Calabrese, Cassandra; Dommasch, Erica D; Feldman, Steven R; Gladman, Dafna; Kircik, Leon; Lebwohl, Mark; Lo Re, Vincent; Martin, George; Merola, Joseph F; Scher, Jose U; Schwartzman, Sergio; Treat, James R; Van Voorhees, Abby S; Ellebrecht, Christoph T; Fenner, Justine; Ocon, Anthony; Syed, Maha N; Weinstein, Erica J; Gondo, George; Heydon, Sue; Koons, Samantha; Ritchlin, Christopher T.
Afiliação
  • Gelfand JM; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Penns
  • Armstrong AW; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Bell S; National Psoriasis Foundation, Portland, Oregon.
  • Anesi GL; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medic
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon.
  • Calabrese C; Department of Rheumatology and Immunology, Cleveland Clinic, Cleveland, Ohio.
  • Dommasch ED; Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
  • Feldman SR; Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  • Gladman D; Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Kircik L; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Indiana University Medical Center, Indianapolis, Indiana.
  • Lebwohl M; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Lo Re V; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia,
  • Martin G; Dermatology Associates, Maui, Hawaii.
  • Merola JF; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Scher JU; Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and New York University Langone Orthopedic Hospital, New York, New York.
  • Schwartzman S; Department of Rheumatology, Hospital for Special Surgery, New York, New York.
  • Treat JR; Department of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Van Voorhees AS; Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia.
  • Ellebrecht CT; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Fenner J; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Ocon A; Division of Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York.
  • Syed MN; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Weinstein EJ; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Gondo G; National Psoriasis Foundation, Portland, Oregon.
  • Heydon S; National Psoriasis Foundation, Portland, Oregon.
  • Koons S; National Psoriasis Foundation, Portland, Oregon.
  • Ritchlin CT; Division of Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York.
J Am Acad Dermatol ; 84(5): 1254-1268, 2021 05.
Article em En | MEDLINE | ID: mdl-33422626
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos